Courts May Not Rule on Invalidity of Unasserted Claims
Client Alert | 1 min read | 09.09.08
In 800 Adept, Inc. v. Murex Securities, Ltd., et al. (Nos. 2007-1272, -1356; August 29, 2008), the Federal Circuit affirms a trial court's judgment of invalidity of certain asserted patent claims, reverses the trial court's judgment of invalidity with respect to unasserted patent claims and of tortious interference, and vacates the trial court's judgment on infringement and invalidity of certain claims.
In reversing the trial court's judgment of invalidity on the unasserted claims, the Federal Circuit determines that the unasserted claims were not placed at issue in the litigation and, therefore, the trial court erred in ruling on the validity of the claims. The Court noted that the assertions of validity must have been "actually litigated by the parties" for there to be a finding of invalidity.
In construing claims as the basis for vacating the finding of infringement, the Federal Circuit uses the prosecution history to support the construction of claims discerned from the claim language and written description, even though the particular claim limitation being construed was not part of the prosecution history at the time certain statements were made. The court finds that since the applicant was "quite clear throughout prosecution that his invention" operated in a certain way, it can be used to support the claim construction discerned from other intrinsic evidence.
Contacts
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26

